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Deciphering the biology of IgG4-related 
disease: specific antigens and disease?
Debashis Haldar,1 Gideon M Hirschfield2
Immunoglobulin G4-related disease 
(IgG4-RD) is the name applied to a corti-
costeroid and/or B-cell depletion respon-
sive illness, in which patients present with 
the consequences of usually multiorgan, 
relapsing and remitting, fibroinflamma-
tion.1 The disease is histologically charac-
terised by obliterative phlebitis, storiform 
fibrosis and a dense lymphoplasmacytic 
infiltrate.2 IgG4-RD is not a new disease, 
but is benefiting from the application of 
new technologies in the pursuit of better 
biological understanding. The histologic 
enrichment of IgG4-expressing plasma 
cells is a diagnostic hallmark of disease 
that additionally serves as a biological 
phenomenon driving scientific evalua-
tion.3 Key disease themes have evolved to 
include a large clonal expansion of acti-
vated plasmablasts and CD4+ cytotoxic, 
inflammatory and profibrotic lympho-
cytes. Therapeutically, a reduced frequency 
of CD4+ cytotoxic lymphocytes are seen 
after B-cell depletion; such therapy may 
consequently impact on antigen presenta-
tion.4–6 To date, the activity of IgG4-RD is 
not readily tracked by disease biomarkers 
with even serum IgG4 concentration 
remaining an imperfect diagnostic and 
prognostic tool for many patients.7 
IgG4 molecules have structural and 
functional characteristics suggesting 
anti-inflammatory and tolerance-inducing 
effects,8 9 and in IgG4-RD a reported oligo-
clonal reactivity to multiple antigens.4 10 In 
Gut, Hubers et al describe a body of work 
that identifies the first IgG4 autoantibody 
against an antigen which appears to be 
specific to IgG4-RD (IgG4-associated chol-
angitis (IAC) and autoimmune pancreatitis 
(AIP)), at the exclusion of its major differ-
ential diagnoses: primary sclerosing chol-
angitis and cholangiocarcinoma.11 The 
authors demonstrate that patients with 
IgG4-RD raise IgG1 and IgG4 in their sera 
that recognise a 56 kDa cytosolic protein 
in an immortalised cell line lysate (H69 
cholangiocytes) and in human liver lysate. 
Both IgG1 and IgG4 antibodies recognise 
the same 56 kDa protein, and subsequent 
label-free quantitative liquid chromatog-
raphy-tandem mass spectrometry anal-
ysis and immunoprecipitation identifies 
the cytosolic protein, Annexin A11, as 
the target. Annexin A11 IgG4 antibodies 
were also found in sera from patients with 
IgG4-sialadenitis, in the absence of IAC or 
AIP, suggesting the target antigen to not be 
site specific.
This work is in the context of next-gen-
eration sequencing studies—a technique 
that has enabled identification of immu-
noglobulin clones within a restricted 
repertoire—yielding strong evidence to 
support an antigen-driven process driving 
the pathology of IgG4-RD. An exam-
ination of circulating plasmablasts in 
those with active IgG4-RD has found the 
expanded pool of cells to have undergone 
class switching to IgG4, to be oligoclo-
nally restricted4 10 12 13 and to be subject 
to extensive somatic hypermutation.10 
Flow cytometric evaluation of circu-
lating IgG4+ B cells confirms increased 
numbers of blood IgG4+ memory B cells 
with reduced expression of CD27 and 
CXCR5 and increased signs of antibody 
maturation.14 In affected tissue, CD4+ 
T cells constitute the most abundant cell 
type, and an analysis of the nature of 
these cells in disease revealed prominent 
clonal expansion of CD4+ T cells with 
a cytolytic phenotype.5 These findings in 
concert strongly suggest an antigen-driven 
process that requires critical T cell and 
B cell interaction.15
Nevertheless, the number and nature 
(foreign or self) of the antigens that drive the 
disease remains a subject for ongoing study, 
collaboration and cross-validation. Dutch 
and UK patient questionnaires revealed 
an association with chronic exposure to 
industrial dusts, gases, oils, solvents and 
pesticides in ‘blue-collar’ professionals—
though further work to elucidate candidate 
antigens and causality is important.16 A 
series of prior studies implicated molecular 
mimicry between antigens on Helicobacter 
pylori and self (eg, α-carbonic anhydrase of 
H. pylori and human carbonic anhydrase II) 
to drive disease.17–19 However, an associa-
tion between exposure to H. pylori infec-
tion and IgG4-RD has since been strongly 
disputed.20 Similarly, lactoferrin, pancreatic 
secretory trypsin inhibitors21 22 and pancre-
atic trypsinogens22 have been reported to be 
associated with AIP, though all of these have 
lacked specificity or sensitivity to IgG4-RD, 
and the nature of the autoantibody has not 
been further examined.
Notwithstanding these shortcomings, 
there is compelling evidence of extant 
autoantigens in disease. The passive 
transfer of purified human immuno-
globulins (IgG1 and IgG4) from people 
with active IgG4-RD into neonatal mice 
led to binding, and subsequent damage 
to exocrine organs (salivary gland and 
pancreas).23 Using cloned immunoglobu-
lins from IgG4-RD patients’ dominantly 
expanded plasmablasts in single cell sorted 
plasmablasts, investigators were able to 
demonstrate the secreted monoclonal 
antibodies to be self-reactive versus a cyto-
solic cellular component.10 However, the 
identity of the cytosolic antigen in this 
study was not determined.
Thus, the identification of specific 
antibodies against a cytosolic target by 
Hubers is consistent with findings from 
others.10 However, why Annexin A11 
would be targeted still demands explana-
tion. It is an intracellular protein, so it 
would follow that the antigen would only 
be presented to the antibody in the event 
of cellular damage. Furthermore, there 
is no obvious clue as to how binding to 
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Annexin A11 would influence pathology. 
Annexins are a family of calcium-depen-
dent phospholipid-binding proteins—
their role in a fibroinflammatory disease 
is unclear, though, as the authors point 
out, autoantibodies against Annexin 
A11 have also been demonstrated in 
systemic lupus erythematosus, systemic 
sclerosis and primary antiphospholipid 
syndrome.24
Some caution must remain about the 
observations because there is a lack of vali-
dation in an external cohort, and of the 50 
patients with IgG4-RD, only 9 had sera that 
reacted to Annexin A11—the authors have 
rightly not presented this as a diagnostic 
test. Validating this selective finding and 
understanding whether and how it relates to 
disease pathogenesis is key to appreciating 
the long-term impact of the work. The same 
group have published elegant work demon-
strating dominant IgG4+ B-cell receptor 
clones accurately distinguish patients with 
IAC and AIP from primary sclerosing chol-
angitis and cholangiocarcinoma.13 IgG4+ 
B-cell receptor clones constituted a greater 
proportion of the total IgG+ repertoire in 
patients with IgG4-RD—and there were 
multiple clones, suggesting that there may 
be multiple antigens driving the observed 
response. Furthermore, the longitudinal 
examination of plasmablast clones in 
patients who have relapsing disease after 
successful initial treatment with B-cell 
depletion therapy (rituximab) has shown 
that the circulating plasmablasts that 
re-emerge are clonally distinct and exhibit 
enhanced somatic mutation compared 
with the initial circulating plasmablasts in 
the same patients.10 It is unclear whether 
the same antigens are recognised during 
the initial disease process and at the time of 
relapse. This raises the question as to how 
to measure and understand the significance 
of specific antigens in the disease process.
The causal relationship between the 
observed immunoglobulin response and 
pathology remains another hole in our 
knowledge. Hubers demonstrates that 
IgG4 from sera of patients diminishes 
IgG1 binding to Annexin A11.11 The 
authors speculate that IgG4 may act to 
dampen the IgG1-mediated pathogenesis 
in response to Annexin A11 binding—
supporting an anti-inflammatory role for 
IgG4 in IgG4-RD. This follows published 
work in 2016, where the investigators 
demonstrated the pathogenicity of circu-
lating IgG in patients with IgG4-RD by 
the passive transfer IgG1 and IgG4 into 
neonatal mice by subcutaneous injection.23 
Both IgG1 and IgG4 bound to murine 
pancreas and salivary glands and led to 
subsequent damage, yet the effect was 
more pronounced in mice injected with 
patient IgG1. However, the potent patho-
genic effects of patient IgG1 were signifi-
cantly blunted by simultaneous injection 
of patient IgG4. It seems as though IgG4, 
though pathogenic, can competitively bind 
to target organs in preference to IgG1 and 
dampen its exaggerated effects.
The tolerogenic effects of IgG4 in 
IgG4-RD remain speculative, although 
figure 1 Immunoglobulin G4-related disease (IgG4-RD) and immune pathways to 
therapy. Naïve B cells are activated by exposure to antigens. In tertiary lymph nodes or in tertiary 
lymphoid tissue within an affected tissue, T follicular helper (Tfh) cells help B cells differentiate 
into antibody secreting cells. Interleukins (IL) 4, 10 and 21 are critical to B-cell affinity maturation, 
class switching and clonal expansion. At the site of disease, B cells are thought to interact with 
cytolytic T cells by the mutual expression of signalling lymphocytic activation molecule 7 (SLAM7). 
These effector T cells secrete profibrogenic cytokines that may be critical to subsequent storiform 
fibrosis, and cytolytic enzymes. The exact nature of the B cell to cytotoxic T cell interaction is still 
unclear. Therapy targeting CD20 (rituximab) leads to a reduction of plasmablasts as a consequence 
of killing their parent cells; plasmablasts do not express CD20. XmAb587 1 is a monoclonal 
antibody therapy that targets CD19 and enhances FcγRIIb-mediated inhibition—a receptor 
that inhibits B-cell function. A phase II trial examining the effect of XmAb5871 in IgG4-RD has 
completed enrolment. Elotuzumab leads to SLAM7-induced antibody directed cellular cytotoxicity 
in multiple myeloma. The utility of elotuzumab in IgG4-RD is currently only theoretical. Other 
therapies that may interfere with the pathogenic process are beyond the scope of this article, but 
could include therapy targeting the BAFF APRIL pathway (belimumab, atacicept); BAFF is critical 
for B-cell survival. Ag, antigen; APRIL, a proliferation-inducing ligand; BAFF, B-cell activating factor; 
BCR, B-cell receptor; CXCR5, chemokine receptor type 5; MHC, major histocompatibility complex; 
TCR, T cell receptor.
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they are well established in other disease 
settings.25 Peculiarities of the structure 
of IgG4 subclass lend itself to an anti-in-
flammatory role. Weaknesses between 
the heavy chains allow it to dissociate as 
two half molecules and associate with 
another IgG4 half molecule—a phenom-
enon known as ‘Fab arm exchange’.8 This 
results in a functionally monovalent IgG 
with bispecificity—thereby restricting the 
formation of immune complexes. More-
over, IgG4 has poor affinity to Fc-gamma 
receptors on effector cells, and to C1q—
rendering them unable at activating the 
classical complement pathway.9 The classic 
example of IgG-mediated immune toler-
ance is seen in beekeepers, which are natu-
rally exposed to high levels of bee venom 
allergen. Tolerant individuals secrete high 
concentrations of venom-specific IgG4 
as opposed to other IgG subclasses and 
IgE.26 27 IgG4 is thought to competitively 
bind to the allergen in preference to IgE, 
thereby inhibiting IgE-mediated immune 
complex formation and mast-cell acti-
vation. Conversely, the immune-damp-
ening effects of IgG4 can interfere with 
beneficial humoral responses. Mela-
noma cells secrete interleukin (IL)-4 and 
IL-10 to direct a modified T helper cell-2 
response.28 Secreted IgG4 can block the 
effects of melanoma-specific IgG1, which 
are potent activators of macrophages 
and thus capable of initiating tumour 
cell death. Consequently, tumour-spe-
cific serum IgG4 concentrations correlate 
to mortality.29 The relevance of IgG4 in 
the pathogenesis of IgG4-RD remains 
confusing. Though serum levels do not 
faithfully correlate to disease activity, the 
excess of circulating IgG4 in active disease 
intuitively argues against a protective 
role. We cannot yet extrapolate whether 
IgG4 antibodies are primarily pathogenic, 
protective or neither.
Seemingly, IgG4-RD is, in part, 
antigen driven, and Hubers’ article in 
this issue of Gut lends a significant boost 
to the evidence base. How this reflects 
host risk continues to evolve and of note 
are conference reports now exploring 
host genetic risk, in robustly collected 
populations. A genome-wide associa-
tion study of IgG4-RD, for example, has 
been performed in a Japanese population 
(Terao et al. International Symposium of 
IgG4-RD and Fibrosis, Feb 2017), and this 
reported three susceptibility loci consis-
tent with antigen-driven disease: HLA-
DRB1, HLA-A and FCGR2B, the latter 
encoding a low affinity receptor for IgG.
IgG4-RD is as much related to IgG4, as it 
is to clonally expanded B-cell populations, 
and an array of T cell subsets, although it is 
not classically preneoplastic, with plasmab-
last expansion being oligoclonal, not poly-
clonal. New technologies have increased 
our understanding of the changes in B-cell 
populations in different stages of the disease, 
but focus is now shifting additionally to 
delineating the role of T cells, in particular 
T follicular helper (Tfh) cells. Tfh cells help 
B cells and augment germinal centre devel-
opment. They play a critical role in immu-
noglobulin somatic hypermutation and class 
switching of antibodies.30 In IgG4-RD, they 
are increased in numbers both in circulation 
and at sites of active disease, with increased 
expression of effector cytokines and regu-
lators.31 In particular, the Tfh2 subset is 
associated with disease activity, the number 
of affected organs, B-cell differentiation 
and serum IgG4 levels, and responds to 
glucocorticoid treatment to parallel clinical 
improvements.32 33 As with the previously 
mentioned clonally expanded cytolytic 
CD4+ T cells, Tfh cell and B cell inter-
actions are critical to the disease process. 
Type 2 Tfh cells seemingly activate B cells, 
which become memory B cells or plasmab-
lasts. Activated B cells and plasmablasts 
can present antigen to CD4+ cytotoxic T 
cells at sites of disease.34 35 Supporting 
this, of course, is the apparently very posi-
tive impact of rituximab (anti-CD20) as a 
therapy.36
IgG4-RD, while very rare, remains an 
informative disease to study. Therapeu-
tically, it portrays an immune-mediated 
disease with treatment options beyond 
corticosteroids, thanks to a greater under-
standing of the underlying pathophysi-
ology (figure 1). Scientifically, it describes 
an evolving immunobiologic process, the 
unravelling of which will aid the under-
standing of all autoimmune disease.
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